BR112018017316A2 - compostos e métodos para a síntese de 5-(n-protegido-triptaminocarboxiamida)-2?-desoxiuridina fosforamidato para incorporação em uma sequência nucleica - Google Patents

compostos e métodos para a síntese de 5-(n-protegido-triptaminocarboxiamida)-2?-desoxiuridina fosforamidato para incorporação em uma sequência nucleica

Info

Publication number
BR112018017316A2
BR112018017316A2 BR112018017316A BR112018017316A BR112018017316A2 BR 112018017316 A2 BR112018017316 A2 BR 112018017316A2 BR 112018017316 A BR112018017316 A BR 112018017316A BR 112018017316 A BR112018017316 A BR 112018017316A BR 112018017316 A2 BR112018017316 A2 BR 112018017316A2
Authority
BR
Brazil
Prior art keywords
synthesis
tryptaminocarboxyamide
incorporation
protected
compounds
Prior art date
Application number
BR112018017316A
Other languages
English (en)
Other versions
BR112018017316B1 (pt
Inventor
Rohloff John
Original Assignee
Somalogic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Somalogic Inc filed Critical Somalogic Inc
Publication of BR112018017316A2 publication Critical patent/BR112018017316A2/pt
Publication of BR112018017316B1 publication Critical patent/BR112018017316B1/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/45—For evaluating or diagnosing the musculoskeletal system or teeth
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T7/00—Image analysis
    • G06T7/0002—Inspection of images, e.g. flaw detection
    • G06T7/0012—Biomedical image inspection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4727—Calcium binding proteins, e.g. calmodulin
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T2207/00—Indexing scheme for image analysis or image enhancement
    • G06T2207/30—Subject of image; Context of image processing
    • G06T2207/30004—Biomedical image processing
    • G06T2207/30024—Cell structures in vitro; Tissue sections in vitro
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T2207/00—Indexing scheme for image analysis or image enhancement
    • G06T2207/30—Subject of image; Context of image processing
    • G06T2207/30004—Biomedical image processing
    • G06T2207/30036—Dental; Teeth

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Theoretical Computer Science (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Quality & Reliability (AREA)
  • Radiology & Medical Imaging (AREA)
  • Dentistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)

Abstract

a presente invenção refere-se a triptamina modificada, trip-tamina-2?-deóxi-uridina (trpdu) e trpdu-fosforamiditas para síntese de oligonucleotídeo, bem como métodos aprimorados de sua síntese e oli-gonucleotídeos que compreendem pelo menos um nucleotídeo trpdu modificado.
BR112018017316-9A 2016-03-14 2017-03-13 Compostos e métodos para a síntese de 5-(n-protegido-triptaminocarboxiamida)-2´- desoxiuridina fosforamidita, oligonucleotídeo e seu método de produção BR112018017316B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662308132P 2016-03-14 2016-03-14
US62/308,132 2016-03-14
PCT/US2017/022007 WO2017160672A1 (en) 2016-03-14 2017-03-13 Compounds and methods for the synthesis of 5-(n-protected-tryptaminocarboxyamide)-2'-deoxyuridine phosphoramidate for incorporation into a nucleic sequence

Publications (2)

Publication Number Publication Date
BR112018017316A2 true BR112018017316A2 (pt) 2019-01-02
BR112018017316B1 BR112018017316B1 (pt) 2022-08-02

Family

ID=58410476

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018017316-9A BR112018017316B1 (pt) 2016-03-14 2017-03-13 Compostos e métodos para a síntese de 5-(n-protegido-triptaminocarboxiamida)-2´- desoxiuridina fosforamidita, oligonucleotídeo e seu método de produção

Country Status (18)

Country Link
US (2) US10634679B2 (pt)
EP (1) EP3430022B1 (pt)
JP (1) JP6853265B2 (pt)
KR (1) KR102269009B1 (pt)
CN (1) CN108779140B (pt)
AR (1) AR107867A1 (pt)
AU (1) AU2017233994B2 (pt)
BR (1) BR112018017316B1 (pt)
CA (1) CA3017853A1 (pt)
DK (1) DK3430022T3 (pt)
ES (1) ES2784946T3 (pt)
HK (1) HK1257431A1 (pt)
IL (1) IL261250A (pt)
MX (1) MX2018011052A (pt)
RU (1) RU2750989C2 (pt)
SG (2) SG11201807079UA (pt)
TW (1) TWI733772B (pt)
WO (1) WO2017160672A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10049447B2 (en) * 2013-11-06 2018-08-14 H. Lee Moffitt Cancer Center and Research Insititute, Inc. Pathology case review, analysis and prediction
WO2024121253A1 (en) * 2022-12-06 2024-06-13 Mihkal Gmbh Novel n,n-dimethyltryptamine (dmt) derivatives and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4899014B2 (ja) * 1995-06-02 2012-03-21 イーシー・テクノロジー・エルエルシー 求核試薬および一酸化炭素を用いるパラジウム触媒ヌクレオシド修飾方法
US5945527A (en) * 1996-05-30 1999-08-31 Nexstar Pharmaceuticals, Inc. Palladium catalyzed nucleoside modification methods using nucleophiles and carbon monoxide
IL138825A (en) * 2000-10-03 2006-06-11 Neurim Pharma 1991 Pharmaceutical preparations containing tryptamine derivatives and similar compounds, and such new compounds
KR20070061893A (ko) 2004-09-22 2007-06-14 트리패스 이미징, 인코포레이티드 유방암 예후를 평가하기 위한 방법 및 조성물
US8249326B2 (en) 2005-11-25 2012-08-21 British Columbia Cancer Agency Branch Apparatus and methods for automated assessment of tissue pathology
CA2604317C (en) * 2007-08-06 2017-02-28 Historx, Inc. Methods and system for validating sample images for quantitative immunoassays
US9684001B2 (en) * 2008-02-07 2017-06-20 Ranju Ralhan Biomarkers for head-and-neck cancers and precancers
CN102165489B (zh) * 2008-09-16 2015-11-25 赫斯托克斯公司 生物标志物表达的可再现量化
JP5544833B2 (ja) 2009-11-17 2014-07-09 富士通株式会社 インドール基用保護基
CA3066785A1 (en) * 2010-04-12 2011-10-20 Somalogic, Inc. 5-position modified pyrimidines and their use
AU2013202528B2 (en) * 2010-04-12 2015-07-30 Somalogic Operating Co., Inc. 5-position modified pyrimidines and their use
AU2011248632B2 (en) 2010-04-27 2015-07-02 Prelude Corporation Cancer biomarkers and methods of use thereof
US20140235487A1 (en) 2010-11-12 2014-08-21 William Marsh Rice University Oral cancer risk scoring
EP3553527A1 (en) 2011-03-17 2019-10-16 Cernostics, Inc. Systems and compositions for diagnosing barrett's esophagus and methods of using the same
TWI541249B (zh) * 2011-04-12 2016-07-11 身體邏輯公司 ５－位置經修飾之嘧啶類及彼等之用途
EP2639238A1 (en) 2012-03-15 2013-09-18 Universität Bern Tricyclic nucleosides and oligomeric compounds prepared therefrom
EP2772882A1 (en) * 2013-03-01 2014-09-03 Universite D'angers Automatic measurement of lesions on medical images
WO2014144657A2 (en) 2013-03-15 2014-09-18 Metamark Genetics, Inc. Compositions and methods for cancer prognosis
LT2984108T (lt) * 2013-04-09 2017-11-10 Lykera Biomed, S.A. Anti-s100a7 antikūnai, skirti vėžio gydymui ir diagnozei
US10983126B2 (en) 2013-05-31 2021-04-20 The Brigham And Women's Hospital System and method for analyzing tissue for the presence of cancer using bio-marker profiles
SG11201602063UA (en) 2013-09-24 2016-04-28 Somalogic Inc Multiaptamer target detection
JP6574240B2 (ja) 2014-03-30 2019-09-11 セフィエド 修飾シトシンポリヌクレオチドオリゴマーおよび方法
EP2933639A1 (en) * 2014-04-16 2015-10-21 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts S100p and Hyaluronic acid as biomarkers for metastatic breast cancer
CN106459133B (zh) 2014-06-10 2019-12-06 安捷伦科技有限公司 用于“z核苷酸”的保护基团及其方法
EP3155592B1 (en) * 2014-06-10 2019-09-11 Leland Stanford Junior University Predicting breast cancer recurrence directly from image features computed from digitized immunohistopathology tissue slides
US9298968B1 (en) * 2014-09-12 2016-03-29 Flagship Biosciences, Inc. Digital image analysis of inflammatory cells and mediators of inflammation
WO2016087592A1 (en) * 2014-12-03 2016-06-09 Ventana Medical Systems, Inc. Systems and methods for early-stage cancer prognosis
WO2017012555A1 (zh) * 2015-07-20 2017-01-26 徐敏 光子结构和化学计量学病理***

Also Published As

Publication number Publication date
KR20180116312A (ko) 2018-10-24
RU2750989C2 (ru) 2021-07-07
IL261250A (en) 2018-10-31
MX2018011052A (es) 2019-01-24
TWI733772B (zh) 2021-07-21
JP6853265B2 (ja) 2021-03-31
US20190031702A1 (en) 2019-01-31
AU2017233994B2 (en) 2021-02-18
SG11201807079UA (en) 2018-09-27
CN108779140B (zh) 2022-04-12
HK1257431A1 (zh) 2019-10-18
SG10201911357VA (en) 2020-01-30
RU2018135738A (ru) 2020-04-15
US10634679B2 (en) 2020-04-28
EP3430022A1 (en) 2019-01-23
EP3430022B1 (en) 2020-03-11
US11585816B2 (en) 2023-02-21
AR107867A1 (es) 2018-06-13
TW201734030A (zh) 2017-10-01
JP2019508438A (ja) 2019-03-28
US20190072559A1 (en) 2019-03-07
WO2017160672A1 (en) 2017-09-21
RU2018135738A3 (pt) 2020-07-22
CA3017853A1 (en) 2017-09-21
CN108779140A (zh) 2018-11-09
DK3430022T3 (da) 2020-05-18
KR102269009B1 (ko) 2021-06-28
BR112018017316B1 (pt) 2022-08-02
AU2017233994A1 (en) 2018-08-30
ES2784946T3 (es) 2020-10-02

Similar Documents

Publication Publication Date Title
MX2020001158A (es) Composiciones nucleotidicas modificadas con citidina-5-carboxamida y metodos relacionados con las mismas.
CY1123289T1 (el) Ενωσεις ολιγονουκλεοτιδιων για τη στοχευση του huntingtin mrna
EA201690526A1 (ru) Замещенные нуклеозиды, нуклеотиды и их аналоги
EA201592075A1 (ru) Замещенные нуклеозиды, нуклеотиды и их аналоги
UA113980C2 (uk) Заміщені нуклеозиди, нуклеотиди і їх аналоги
EA201590943A1 (ru) Замещенные нуклеозиды, нуклеотиды и их аналоги
EA201790420A1 (ru) Средства, представляющие собой модифицированную двухнитевую рнк
PE20191351A1 (es) Tratamiento aav de la enfermedad de huntington
BR112017013028A2 (pt) nucleosídeos, nucleotídeos e análogos dos mesmos substituídos
MX2017008184A (es) Nucleosidos sustituidos, nucleotidos y analogos de estos.
BR112017027498A2 (pt) anticorpo, ácido nucleico, composto, composição, e, método para tratamento de um paciente com uma doença.
MX2016007541A (es) Moléculas modificadas de ácido nucleico y usos de las mismas.
PH12015502273A1 (en) Substituted nucleosides, nucleotides and analogs thereof
UA117098C2 (uk) Сполука, що містить модифікований олігонуклеотид
BR112012025872A2 (pt) primidinas modificadas na posição-5 e seu uso
EA201492114A1 (ru) Композиции и способы для модулирования экспрессии генов
EA202090720A1 (ru) ПРОИЗВОДНЫЕ GalNAc
MX2015011779A (es) Nucleosidos biciclicos unidos en puente.
BR112018017316A2 (pt) compostos e métodos para a síntese de 5-(n-protegido-triptaminocarboxiamida)-2?-desoxiuridina fosforamidato para incorporação em uma sequência nucleica
WO2019079637A3 (en) Antisense oligomer compounds
BR112018075869A8 (pt) Oligonucleotídeos que compreendem nucleosídeos modificados
AR121847A2 (es) Compuestos y composiciones para modular la expresión de tau
PL413941A1 (pl) Sposób syntezy i oczyszczania nukleozydu i/lub nukleotydu, zmodyfikowany nukleozyd i/lub nukleotyd, cząsteczka DNA i biblioteka oligonukleotydów zawierające zmodyfikowany nukleozyd i/lub nukleotyd oraz zastosowanie biblioteki oligonuklotydów
FR2906532B1 (fr) Nouvel oligonucleotide marque
TH182360A (pt)

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B25D Requested change of name of applicant approved

Owner name: SOMALOGIC OPERATING CO., INC. (US)

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/03/2017, OBSERVADAS AS CONDICOES LEGAIS